Progyny Inc (PGNY)

Fertility Benefits Growth and Share Buybacks Keep Progyny (PGNY) Earnings in FocusMay 8, 2026 10:58 AM
IH Market News Progyny reported higher first-quarter revenue and profit while expanding its client base and continuing aggressive share repurchase activity. Key Investor Takeaways Progyny, Inc. (NASDAQ:PGNY) posted first-quarter revenue growth and higher net income despite the loss of a previously disclosed large client. The company repurchased 8.8 million shares under its completed $200 million buyback program. PGNY reported 595 fertility and family-building clients, up from 532 a year earlier. Gross margin expanded to 25.3%, reflecting operational efficiencies and lower stock-based compensation expense. Management maintained full-year growth guidance and said early-stage sales activity for 2026 remains favorable. Why PGNY Stock Is in Focus Progyny, Inc. (NASDAQ:PGNY) released first-quarter 2026 results showing modest top-line growth alongside stronger profitability and continued expansion in its fertility and women’s health benefits platform.Revenue increased 1.4% year-over-year to $328.5 million, compared with $324.0 million in the prior-year quarter.The company noted that growth was partially offset by the previously disclosed non-renewal of a large client contract. Excluding revenue tied to that client transition agreement in the prior-year period, revenue increased 12.2%.Fertility benefit services revenue rose 1.5% to $209.4 million, while pharmacy benefit services revenue increased 1.3% to $119.1 million.Gross profit climbed 10% year-over-year to $83.1 million, and gross margin improved to 25.3% from 23.4%.Net income increased to $24.2 million, or $0.29 per diluted share, versus $15.1 million, or $0.17 per diluted share, a year earlier.Adjusted EBITDA declined slightly to $56.6 million from $57.8 million as the company continued investing in platform functionality and member experience initiatives.“We’re pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.“Our current selling season is in its early stages and we’re off to a good start. Activity is healthy, overall pipeline and the early build of new pipeline is substantially favorable versus a year ago, and early commitments are pacing ahead of this time last year, all of which positions us well for this selling season.”The company also highlighted continued share repurchases during the quarter.Progyny bought back more than 5.5 million shares during the first quarter for $116.4 million, completing its previously authorized $200 million repurchase program.Management said the board is currently evaluating a potential new repurchase authorization. Why This Matters for Investors The results may reinforce investor focus on Progyny’s ability to continue growing despite client concentration risks and broader economic uncertainty.The company’s adjusted revenue growth excluding the lapsed client relationship suggests underlying demand for fertility and women’s health benefits remains strong.For investors, client expansion and covered lives growth may be particularly important because they support Progyny’s long-term recurring revenue model tied to employer-sponsored healthcare benefits.Margin expansion could also improve sentiment around operational scalability, especially as the company continues investing in platform enhancements while maintaining profitability.The aggressive share repurchase activity may additionally signal management confidence in the company’s cash generation and balance sheet position.At the same time, investors may continue monitoring utilization trends, employer spending patterns, and the potential impact of macroeconomic conditions on benefit adoption and healthcare usage. What to Watch Next Investors will likely monitor: Progress during Progyny’s 2026 client selling season Potential announcement of a new share repurchase program Growth in covered lives and client additions Member utilization trends across fertility and pharmacy services Margin performance as platform investments continue Execution against full-year revenue and EBITDA guidance Progyny stock price Original: Fertility Benefits Growth and Share Buybacks Keep Progyny (PGNY) Earnings in Focus

🚨NEW STUDY - Fatal Malignant Cardiac Tumors Following COVID-19 mRNA Injection

🛑 Case 1 - A 49-year-old male developed chest pain & breathlessness 4 weeks after his first Pfizer–BioNTech COVID-19 vaccine. Initially treated for pericarditis, he was later diagnosed with malignant… pic.twitter.com/Zt2OkJW6uy— Nicolas Hulscher, MPH (@NicHulscher) March 6, 2025 $PGNY

1 hell of a drop today - ugh!

$PGNY holding up well

They were already mentioned on Investors Business Daily.
Starting to be known. Good growth small cap.

PGNY is an IPO that has flown under the financial awareness radar

I suspect they'll launch an 'awareness campaign' sometime after the 1st

non-stop buying spree today off the low of $23

this is going to $31 quickly

I suspect they will have a large awareness campaign soon

PGNY is expected to announce break even this FY20

IPO retracement finding support around $23 pps

Progyny, Inc. Announces Pricing of Initial Public Offering

Date : 10/25/2019 @ 12:01AM
Source : GlobeNewswire Inc.
Stock : Progyny Inc (PGNY)
Quote : 25.99 0.0 (0.00%)

Progyny (NASDAQ:PGNY)

https://ih.advfn.com/stock-market/NASDAQ/progyny-PGNY/stock-news/80991562/progyny-inc-announces-pricing-of-initial-public

Progyny, Inc., a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a price to the public of $13.00 per share. Progyny is offering 6,700,000 shares and the selling stockholders are offering 3,300,000 shares. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price less the underwriting discount. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “PGNY” on October 25, 2019, and the offering is expected to close on October 29, 2019, subject to customary closing conditions.

J.P. Morgan, Goldman Sachs & Co. LLC and BofA Securities are acting as joint lead book-running managers for the offering. Citigroup is acting as book-running manager for the offering. Piper Jaffray, SVB Leerink and TPG Capital BD, LLC are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attn: Prospectus Department, Telephone: 866-803-9204, Email: prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attn: Prospectus Department, Telephone: 866-471-2526, Facsimile: 212-902-9316, Email: prospectus-ny@ny.email.gs.com; and BofA Securities, One Bryant Park, New York, New York 10036, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Progyny

Progyny is a leading fertility benefits management company in the United States. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive fertility solution can simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation’s leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

Contact

Progyny PR

Selena Yang
media@progyny.com

Progyny IR

James Hart
investors@progyny.com